ALK and Abnormal emotional state: For patients with EGFR or ALK mutations, we adopted the MMSE assessment scale, EORTC QLQ-C30 scale, and DT scale to evaluate the relationship between changes in cognitive function during targeted treatment and QoL and psychological distress and cognitive function’s impact on treatment outcomes.